Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions (NASDAQ: BLFS) opened the Aby J. Mathew Center for Biopreservation Excellence at its expanded Bothell headquarters on November 20, 2025.
The 4,500 square foot facility combines state-of-the-art conference and laboratory space to showcase BioLife's cell processing product portfolio, provide customized training and customer workshops, support internal research, and generate applications data for current and pipeline products.
The Center will also support development of next-generation cryopreservation products that incorporate the company's proprietary ice recrystallization inhibitor (IRI) technology acquired earlier in 2025, and serve as a hub for industry collaboration and biopreservation best practices.
BioLife Solutions (NASDAQ: BLFS) announced that management will participate in multiple investor conferences in November and December 2025, including Raymond James Napa Small Cap Symposium on Nov 17, 2025, Stephens Annual Investment Conference on Nov 18–20, 2025, Jefferies Global Healthcare Conference on Nov 17–20, 2025, Furey Research Partners Hidden Gems Conference on Nov 24–25, 2025, Wolfe Research Small & Mid-Cap Conference on Dec 2–3, 2025, and Northland Growth Conference on Dec 16, 2025.
The company said its refreshed investor presentation is now available on the Investor Relations section of the company website.
BioLife Solutions (Nasdaq: BLFS) reported Q3 2025 results showing continued growth in its core cell processing business. Cell Processing revenue rose 33% YoY to $25.4M, total revenue was $28.1M (up 31% YoY), and adjusted EBITDA was $7.8M (28% of revenue). GAAP net income for Q3 was $0.6M. Management raised 2025 Cell Processing revenue guidance to $93.0M–$94.0M and total revenue guidance (post-evo sale) to $95.0M–$96.0M. The company completed the sale of its evo cold chain business for $25.5M in early October 2025.
BioLife Solutions (NASDAQ: BLFS) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will host a conference call and live webcast the same day at 4:30 PM ET (1:30 PM PT) to present an overview of financial results and a general business update.
Investors can access the live webcast at the company Investor Relations page and join the call via toll-free 1-833-630-0431 or international 1-412-317-1808. A replay will be available about two hours after the call and archived on the investor site for 90 days.
BioLife Solutions (Nasdaq: BLFS) announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies (f/k/a SAVSU Technologies), to Peli BioThermal for $25.5 million in cash, subject to customary adjustments.
The company said the divestiture will streamline its product portfolio and operations to concentrate resources on high-margin recurring revenue in its core cell and gene therapy tools and services business.
BioLife Solutions (Nasdaq: BLFS) reported strong Q2 2025 financial results with total revenue of $25.4 million, up 29% year-over-year. Cell Processing revenue reached $23.0 million, increasing 28% from Q2 2024. The company achieved a GAAP gross margin of 62% and adjusted EBITDA of $6.1 million (24% of revenue).
Despite reporting a GAAP net loss of $15.8 million, largely due to a one-time $15.5 million IPR&D expense from the PanTHERA acquisition, BioLife raised its 2025 revenue guidance to $100.0-103.0 million. The company's biopreservation media is now embedded in 16 approved therapies and supports over 250 clinical trials, including 30+ in Phase III.
[ "Cell Processing revenue grew 28% year-over-year to $23.0 million", "Strong adjusted EBITDA of $6.1 million, representing 24% of revenue", "Raised full-year 2025 revenue guidance to $100.0-103.0 million", "Biopreservation media embedded in 16 approved therapies", "70% market share in commercially sponsored clinical trials", "Healthy cash position of $100.2 million as of June 30, 2025" ]BioLife Solutions (NASDAQ: BLFS), a leading bioproduction products supplier for cell and gene therapy, has made a $2 million strategic investment in Pluristyx through convertible notes. The investment includes a board observer seat and potential future acquisition rights.
Pluristyx, a Seattle-based company, develops innovative induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment aligns with BioLife's strategy of exploring biological assays as a product portfolio expansion, following similar investments in Sexton and PanTHERA.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, will release its second quarter 2025 financial results after market close on Thursday, August 7, 2025.
The company will host a conference call and webcast at 4:30 PM ET where management will discuss financial results and provide a business update. Investors can access the webcast through BioLife's website or join via phone using the provided toll-free numbers.
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy market, has announced its participation in five upcoming investor conferences in May and June 2025. The company will attend the Craig-Hallum Institutional Investor Conference (May 28, Minneapolis), Benchmark Healthcare House Call Virtual Conference (May 29), Jefferies Global Life Sciences Conference (June 3-5, New York), Wolfe Research Small & Mid-Cap Conference (June 5, New York), and Northland Growth Conference (June 25, Virtual).
BioLife Solutions (NASDAQ: BLFS), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, has provided updated dial-in information for their earnings call scheduled for today at 4:30pm ET. U.S. participants can dial 1-833-630-0431, while international callers should use 1-412-317-1808.
BioLife Solutions specializes in providing solutions that maintain the health and function of biological materials throughout the collection, development, manufacturing, and distribution processes, supporting the commercialization of new therapies in the CGT market.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
